Skip to Content
MilliporeSigma
  • BDNF signaling in the VTA links the drug-dependent state to drug withdrawal aversions.

BDNF signaling in the VTA links the drug-dependent state to drug withdrawal aversions.

The Journal of neuroscience : the official journal of the Society for Neuroscience (2014-06-06)
Hector Vargas-Perez, Amine Bahi, Mary Rose Bufalino, Ryan Ting-A-Kee, Geith Maal-Bared, Jenny Lam, Ahmed Fahmy, Laura Clarke, Jennifer K Blanchard, Brett R Larsen, Scott Steffensen, Jean-Luc Dreyer, Derek van der Kooy
ABSTRACT

Drug administration to avoid unpleasant drug withdrawal symptoms has been hypothesized to be a crucial factor that leads to compulsive drug-taking behavior. However, the neural relationship between the aversive motivational state produced by drug withdrawal and the development of the drug-dependent state still remains elusive. It has been observed that chronic exposure to drugs of abuse increases brain-derived neurotrophic factor (BDNF) levels in ventral tegmental area (VTA) neurons. In particular, BDNF expression is dramatically increased during drug withdrawal, which would suggest a direct connection between the aversive state of withdrawal and BDNF-induced neuronal plasticity. Using lentivirus-mediated gene transfer to locally knock down the expression of the BDNF receptor tropomyosin-receptor-kinase type B in rats and mice, we observed that chronic opiate administration activates BDNF-related neuronal plasticity in the VTA that is necessary for both the establishment of an opiate-dependent state and aversive withdrawal motivation. Our findings highlight the importance of a bivalent, plastic mechanism that drives the negative reinforcement underlying addiction.

MATERIALS
Product Number
Brand
Product Description

Supelco
Morphine sulfate salt solution, 1.0 mg/mL in methanol, drug standard
Supelco
Electrolyte solution, nonaqueous, 2 M LiCl in ethanol
Sigma-Aldrich
Muscimol hydrobromide, ≥98% (HPLC), solid
Sigma-Aldrich
Lithium-7Li chloride, 99 atom % 7Li, 99% (CP)
Sigma-Aldrich
BDNF human, Carrier free, recombinant, expressed in E. coli, ≥95% (SDS-PAGE), suitable for cell culture
Sigma-Aldrich
Lithium chloride, AnhydroBeads, −10 mesh, 99.998% trace metals basis
Supelco
Heroin, analytical standard, ≥98% (HPLC)
Sigma-Aldrich
Lithium chloride, AnhydroBeads, −10 mesh, ≥99.9% trace metals basis
Sigma-Aldrich
Brain-derived neurotrophic factor human, BDNF, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
Lidocaine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Lidocaine, European Pharmacopoeia (EP) Reference Standard
Supelco
Lidocaine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Lithium chloride, ReagentPlus®, 99%
Sigma-Aldrich
Lithium chloride solution, 8 M, Molecular Biology, ≥99%
Supelco
Lithium chloride solution, 1 M in ethanol
Sigma-Aldrich
Lithium chloride, BioUltra, Molecular Biology, anhydrous, ≥99.0% (AT)
Sigma-Aldrich
Lithium chloride, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, 99%
Sigma-Aldrich
Lithium chloride, ACS reagent, ≥99%
Supelco
Lidocaine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Lithium chloride, powder, ≥99.98% trace metals basis
Sigma-Aldrich
Lithium chloride, Molecular Biology, ≥99%
Sigma-Aldrich
Lidocaine, powder
Sigma-Aldrich
Lithium chloride, BioXtra, ≥99.0% (titration)
Sigma-Aldrich
Lithium chloride, puriss. p.a., anhydrous, ≥99.0% (AT)
Sigma-Aldrich
Lithium chloride, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99%
Sigma-Aldrich
Lidocaine, analytical standard
USP
Lidocaine, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
ProBDNF human, recombinant, expressed in E. coli, ≥95% (SDS-PAGE), ≥95% (HPLC)